

Order: +86 021-68455258/50432826/50432825

Toll-free: +86 400 627 9288 Email: service@genomeditech.com

# **Product Sheet**

# **H\_ACE2 HEK-293T Cell Line**

Catalog number: GM-C12968

Version 3.3.1.241203

H\_ACE2 HEK-293T Cell Line is a clonal stable HEK-293T cell line that constitutively **Description** 

expresses the human ACE2 gene, constructed using lentiviral technology.

**Quantity** 5E6 Cells per vial,1 mL

**Product Format** 1 vial of frozen cells

**Shipping** Shipped on dry ice

Storage Conditions Liquid nitrogen immediately upon receipt

Target Human\_ACE2

Gene ID/Uniprot ID Q9BYF1-1

Host Cell HEK-293T

**Recovery Medium** DMEM+10% FBS+1% P.S

Growth medium DMEM+10% FBS+1% P.S+0.75 μg/mL Puromycin

Note None

Freezing Medium 90% FBS+10% DMSO

**Growth properties** Adherent

Growth Conditions 37°C, 5% CO<sub>2</sub>

**Mycoplasma Testing** The cell line has been screened to confirm the absence of Mycoplasma species.

**Safety considerations** Biosafety Level 2

Note It is recommended to expand the cell culture and store a minimum of 10 vials at an early

passage for potential future use.



Order: +86 021-68455258/50432826/50432825

Toll-free: +86 400 627 9288 Email: service@genomeditech.com

#### **Materials**

Reagent	Manufacturer/Catalogue No.
DMEM	Gibco/C11995500BT
Fetal Bovine Serum	Cegrogen biotech/A0500-3010
Pen/Strep	Thermo/15140-122
Puromycin	Genomeditech/GM-040401
Anti-ACE2 hIgG4 Antibody(3E8)	Genomeditech/GM-32019AB

### **Figures**





Figure 1 | H\_ACE2 HEK-293T Cell Line (Cat. GM-C12968) was determined by flow cytometry using Anti-ACE2 hIgG4 Antibody(3E8) (Cat. GM-32019AB).



H\_ACE2 HEK-293T Cell Line (GM-C12968/24176CP3) at lower cell passage number (e.g., p=3) and higher passage cells (e.g., p=10) were infected by different amounts of SARS-CoV-2 Spike Pseudotyped Virus(GM-0220PV07/VF27999), respectively.


Figure 2 | H\_ACE2 HEK-293T Cell Line (GM-C12968/24176CP3) at lower cell passage number (e.g., p=3) and higher passage cells (e.g., p=10) were infected by different amounts of SARS-CoV-2 Spike Pseudotyped Virus (GM-0220PV07/VF27999), respectively.



Order: +86 021-68455258/50432826/50432825

Toll-free: +86 400 627 9288

Email: service@genomeditech.com



SampleID	Geometric Mean : FL11-H
HEK-293T anti_ACE2+APC-2nd Ab	1768
HEK-293T H_ACE2 H_IgG+APC-2nd Ab	1813
HEK-293T H_ACE2 anti_ACE2+APC-2nd Ab CP6	116182
HEK-293T H_ACE2 anti_ACE2+APC-2nd Ab CP15	104163

Figure 3 | The passage stability of the H\_ACE2 HEK-293T Cell Line (Cat. GM-C12968) was determined by flow cytometry using Anti-ACE2 hIgG4 Antibody(3E8) (Cat. GM-32019AB).

#### **Cell Recovery**

Recovery Medium: DMEM+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

- a) Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 3 minutes).
- b) Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
- c) Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.
- d) Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.
- e) Incubate the culture at 37°C in a suitable incubator. A 5% CO<sub>2</sub> in air atmosphere is recommended if using the medium described on this product sheet.

## **Cell Freezing**

Freezing Medium: 90% FBS+10% DMSO

- a) Centrifuge at 176 x g for 3 minutes to collect cells.
- b) Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.
- c) Aliquot 1 mL into each vial.
- d) Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.



Order: +86 021-68455258/50432826/50432825

Toll-free: +86 400 627 9288 Email: service@genomeditech.com

#### Cell passage

Growth medium: DMEM+10% FBS+1% P.S+0.75 µg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

- a) Remove and discard culture medium.
- b) Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.
- c) Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 30 to 60 seconds at 37°C).
- d) Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- e) Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.
- f) After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.
- g) Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:5 - 1:8 is recommended

Medium Renewal: Every 1 to 2 days

#### **Notes**

a) Upon initial thawing, a higher number of dead cells is observed, which is a normal phenomenon. Significant improvement is seen after adaptation. Once the cells reach a stable state, the number of dead cells decreases after subculturing and the cell growth rate becomes stable.

#### **Sequence**

ACE2 Q9BYF1-1

MSSSSWLLLSLVAVTAAQSTIEEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEENVQNMNNAGDKWSA FLKEQSTLAQMYPLQEIQNLTVKLQLQALQQNGSSVLSEDKSKRLNTILNTMSTIYSTGKVCNPDNPQECLLL EPGLNEIMANSLDYNERLWAWESWRSEVGKQLRPLYEEYVVLKNEMARANHYEDYGDYWRGDYEVNGV DGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAYPSYISPIGCLPAHLLGDMWGRFWTNLYSLTVP FGQKPNIDVTDAMVDQAWDAQRIFKEAEKFFVSVGLPNMTQGFWENSMLTDPGNVQKAVCHPTAWDLGK GDFRILMCTKVTMDDFLTAHHEMGHIQYDMAYAAQPFLLRNGANEGFHEAVGEIMSLSAATPKHLKSIGLL SPDFQEDNETEINFLLKQALTIVGTLPFTYMLEKWRWMVFKGEIPKDQWMKKWWEMKREIVGVVEPVPHD ETYCDPASLFHVSNDYSFIRYYTRTLYQFQFQEALCQAAKHEGPLHKCDISNSTEAGQKLFNMLRLGKSEPW TLALENVVGAKNMNVRPLLNYFEPLFTWLKDQNKNSFVGWSTDWSPYADQSIKVRISLKSALGDKAYEWN DNEMYLFRSSVAYAMRQYFLKVKNQMILFGEEDVRVANLKPRISFNFFVTAPKNVSDIIPRTEVEKAIRMSRS RINDAFRLNDNSLEFLGIQPTLGPPNQPPVSIWLIVFGVVMGVIVVGIVILIFTGIRDRKKKNKARSGENPYASI DISKGENNPGFQNTDDVQTSF\*



Order: +86 021-68455258/50432826/50432825

Toll-free: +86 400 627 9288

Email: service@genomeditech.com

#### **Related Products**

其他-SARS-COV-2	
Anti-ACE2 hIgG4 Antibody(3E8)	Anti-SARS-CoV-2 hIgG1 Antibody (Imdevimab)

#### **Limited Use License Agreement**

Genomeditech (Shanghai) Co., Ltd grants to the Licensee all intellectual property rights, exclusive, non-transferable, and non-sublicensable rights of the Licensed Materials; Genomeditech (Shanghai) Co., Ltd will retain ownership of the Licensed Materials, cell line history packages, progeny, and the Licensed Materials including modified materials.

Between Genomeditech (Shanghai) Co., Ltd, and Licensee, Licensee is not permitted to modify cell lines in any way. The Licensee shall not share, distribute, sell, sublicense, or otherwise provide the Licensed Materials, or progenitors to third parties such as laboratories, departments, research institutions, hospitals, universities, or biotechnology companies for use other than for the purpose of outsourcing the Licensee's research.

Please refer to the Genomeditech Cell Line License Agreement for details.